A Phase 3 interventional study of capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) in Parkinson's Disease, sponsored by Novartis. Completed at 60 sites in 8 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-05-17.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.
Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 7 in phase 3, and was the 3rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
By country, each count listing its studies:
Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2004; this study’s year is marked. 3 started in 2005.
This study's enrollment of 493 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 24 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 24 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
21 studies in Parkinson Disease by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 21 studies in Parkinson Disease by Novartis, this one is the 3rd largest by enrollment, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 3rd registered.
Novartis’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing carbidopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level 100 mg t.i.d.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug pages: Carbidopa · Levodopa · Entacapone
Also known as: Stalevo, CELC200
Symptom control change from baseline to week 39
Change from baseline to week 39 in activities of daily living
Change from baseline to week 39 in motor function
Change from baseline to week 39 in mental acuity
Change from baseline to week 39 in incidence of dyskinesia and wearing off
The record gives a start of Aug 2005, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone